

# NIH Public Access

Author Manuscript

*Chem Commun (Camb).* Author manuscript; available in PMC 2010 November 21

Published in final edited form as:

Chem Commun (Camb). 2009 November 21; (43): 6607–6609. doi:10.1039/b908788e.

## Mesoporous Zirconium Oxide Nanomaterials Effectively Enrich Phosphopeptides for Mass Spectrometry-based

### Phosphoproteomics

Cory A. Nelson<sup>a,b</sup>, Jeannine R. Szczech<sup>b</sup>, Qingge Xu<sup>a</sup>, Mathew J. Lawrence<sup>a</sup>, Song Jin<sup>b</sup>, and Ying Ge<sup>a</sup>

Cory A. Nelson: ; Jeannine R. Szczech: ; Qingge Xu: ; Mathew J. Lawrence: ; Song Jin: jin@chem.wisc.edu; Ying Ge: yge@physiology.wisc.edu

<sup>a</sup>Human Proteomics Program, School of Medicine and Public Health University of Wisconsin-Madison 1300 University Ave., Madison, WI, USA

<sup>b</sup>Department of Chemistry University of Wisconsin-Madison 1300 University Ave., Madison, WI, USA

#### Abstract

This work represents the first use of mesoporous zirconium oxide nanomaterials for highly effective and selective enrichment of phosphorylated peptides.

Reversible protein phosphorylation is a ubiquitous post-translational modification that plays a vital role in the control of many biological processes such as cellular growth, division, and signaling.<sup>1</sup> Aberrant phosphorylation is known to be one of the underlying mechanisms for many human diseases, most notably cancer. <sup>1a,c</sup> Mass spectrometry (MS) has become the most important and powerful tool for the analysis of protein phosphorylation due to its sensitivity, speed, simplicity, separation, and specificity.<sup>2</sup> While MS techniques have been successfully applied to determine the phosphorylation state of a single protein/peptide, MS analysis of phosphorylation on a proteome-wide scale still poses substantial challenges due to the low abundance of phosphoproteins and substoichiometric phosphorylation.<sup>3</sup> Therefore, isolation and enrichment of the phosphoproteins/peptides are essential for MS-based phosphoproteomics.<sup>4</sup> The affinity based method such as immobilized metal ion affinity chromatography (IMAC)<sup>5</sup> using Ga(III), Fe(III), or other metals, has been widely used for phosphopeptides enrichment. Recently microparticles of titanium dioxide (TiO<sub>2</sub>),<sup>6a,b</sup> zirconium oxide (ZrO<sub>2</sub>),<sup>6c</sup> and other metal oxides<sup>6d–e</sup> have demonstrated higher specificity for trapping phosphate than the conventional IMAC beads since such oxides rely on specific and reversible chemisorption of phosphate groups on their amphoteric surface and have less nonspecific binding. Additionally, nanoparticles, such as ZrO<sub>2</sub>, TiO<sub>2</sub>, Fe<sub>2</sub>O<sub>3</sub>, and titania-coated magnetic iron oxide (Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>) nanoparticles, have recently been explored due to their potential higher capacities than the microparticles.<sup>7</sup>

Mesoporous materials are nanostructured materials with pore sizes typically between 2–50 nm.<sup>8</sup> They have extremely large surface areas and have been utilized in many applications such as catalyst support and filtration. Such large surface areas, together with the many active surface sites, can be translated into even higher loading capacity for binding phosphate groups than micro- and nanoparticles.<sup>9</sup> In addition to their well-ordered nanoscale porous structures and

<sup>©</sup> The Royal Society of Chemistry [year]

Correspondence to: Song Jin, jin@chem.wisc.edu; Ying Ge, yge@physiology.wisc.edu.

flow-through capacity, they are chemically stable and can be easily prepared at reasonable cost. All these attributes would make them ideal for applications in MS-based phosphoroproteomics. Herein, we report the utility of  $ZrO_2$  nanomaterials for simple and efficient enrichment of phosphopeptides with high specificity. This is the first application of mesoporous  $ZrO_2$  nanomaterials for phosphopeptide enrichment.

We chose ZrO<sub>2</sub> metal oxide because of its known amphoteric surface properties, <sup>10</sup> which facilitates preferable and reversable binding and release of the phosphate groups under different pH of the solutions. We synthesized mesoporous materials using commercially available Pluronic® triblock copolymer surfactant F127 to form ordered nanoscale micellular structures in alcohol solutions to template the controlled hydrolysis of the metal precursors in a so-called evaporation induced self assembly (EISA) process.<sup>8b, 8c†</sup> The calcined materials were characterized with scanning electron microscopy (SEM, Fig. S1), transmission electron microscopy (TEM) and small angle x-ray scattering (SAXS) to examine the quality of the mesoporous structure and determine pore size and periodicity.

Fig. 1a clearly shows the ordered mesostructure of  $ZrO_2$ . Average pore size was determined from TEM images to be 5.8 nm with an average periodicity determined from SAXS and TEM to be 8.2 nm. Brunauer-Emmett-Teller (BET) analysis of N<sub>2</sub> absorption experiments revealed that the mesoporous  $ZrO_2$  has a high surface areas of 72 m<sup>2</sup>/g, which is in good agreement with that previously reported for meosporous  $ZrO_2$  templated with this block copolymer F127.<sup>8e</sup> The high surface area, which can be further increased when other surfactants are used, <sup>8</sup> makes mesoporous materials good candidates for phosphopeptide enrichment.

The enrichment procedures using mesoporous metal oxides (Scheme 1) include: (a) pretreatment of mesoporous oxides, (b) equilibration of the peptide mixtures with mesoporous oxides at pH 2.0, (c) separation of the unbound non phosphopeptides by removing the supernatant solutions at pH 8.5, and (d) elution of the phosphopeptides at pH 11.5.<sup>†</sup> Strong binding of the phosphate groups to  $ZrO_2$  surface allows the phosporylated peptides to remain absorbed on the mesoporous materials until eluted with a high pH solution. Non-specific binding, presumably from acidic peptides, has been minimized by optimizing the buffers used in binding, washing, and eluting steps. The best results were achieved with a binding buffer solution of 20 mg/mL phthalic acid in 0.1% trifluoroacetic acid in 50/50 water/acetonitrile (pH 2.0), washing twice with 50 mM ammounium bicarbonate in 50/50 water/acetonitrile (pH 8.5), and an eluting buffer of ammonium hydroxide (pH 11.5). The eluted phosphopeptide solutions were then adjusted properly to be analyzed by electrospray (ESI) MS. The phosphopeptides were first detected based on the facile neutral loss of phosphoric acid (H<sub>3</sub>PO<sub>4</sub>) or metaphosphoric acid (HPO<sub>3</sub>) from phosphorylated serine/threonine/tyrosine phosphopeptides generated from collisionally activated dissociation (CAD), a conventional tandem mass spectrometry (MS/MS). The sequences of the enriched phosphopeptides were further confirmed and the phosphorylation sites within phosphopeptides were unambiguously localized by both CAD and electron capture dissociation (ECD) (Fig. S2). Fragment ions were assigned with very high mass accuracy (<5 ppm) (Table S2, S3). The specificity of the enrichment enabled easy isolation of the peaks and the large trapping capacity of the mesoporous materials yielded highly abundant peaks which, upon fragmentation, gave complete or nearly complete coverage for the peptides of interest. Unlike CAD which tends to knock off the phosphate groups, ECD<sup>11</sup> is a nonergodic MS/MS technique known to preserve labile phosphorylation making it extremely powerful for facile localization of phosphorylation sites. However, ECD requires higher signal-to-noise ratios for precursor ions thus demands efficient enrichment processes for its effective applications in phosphoproteomics.<sup>6c</sup>

<sup>&</sup>lt;sup>†</sup>Electronic Supplementary Information (ESI) available: ZrO<sub>2</sub> synthesis, and phosphopeptide enrichment details and results, with phosphopeptide sequences, tandem MS spectra and tables, and additional SEM of the materials. See DOI: 10.1039/b000000x/

Chem Commun (Camb). Author manuscript; available in PMC 2010 November 21.

The enrichments using mesoporous ZrO<sub>2</sub> are extremely effective as shown by the high resolution Fourier transform (FT) mass spectra of the  $\alpha$ -case digest before and after the enrichment (Fig. S3). Only 8 MS peaks corresponding to 6 phosphopeptides were detected before enrichment (Fig. S3a); all of which are low abundance peaks owing to ion suppression from abundant non phosphopeptides. In contrast, after enrichment with mesoporous ZrO<sub>2</sub> (Fig. S3b), 30 multiply charged MS peaks corresponding to 20 phosphopeptides were detected in a single mass spectrum with much higher signal-to-noise ratios. When enriched with mesoporous  $ZrO_2$  nearly all of the non phosphopeptides were removed leaving only phosphorylated peaks, which substantially enhanced the signal of phosphopeptides. Furthermore, as demonstrated in a side-by-side quantitative comparison (Fig. 2), the mesoporous  $ZrO_2$  materials showed significantly higher specificity and efficiency for phosphopeptide enrichment than the leading commercial IMAC and ZrO2 nanoparticle-based phospho-enrichment methods. After enrichment with the IMAC-based enrichment product (Fig. 2a), 7 multiply charged MS peaks corresponding to 7 phosphopeptides were identified in one MS spectrum. Enrichment with the ZrO<sub>2</sub> packed tips (Fig. 2b) revealed 6 multiply charged MS peaks corresponding to 6 phosphopeptides in one MS spectrum. In contrast, an enrichment with the mesoporous ZrO<sub>2</sub> nanomaterials detected 27 multiply-charged MS peaks corresponding to 19 phosphopeptides (Fig. 2c).

To further evaluate the specificity for phosphopeptides, we tested the mesoporous  $ZrO_2$  using a more complicated mixture with a substantial fraction of non phosphorylated proteins. 5 non phosphoproteins and 7% (by weight of the total proteins) phosphoprotein,  $\alpha$ -casein, (Table S1) were mixed and digested with trypsin to create a complex peptide mixture. Before enrichment many non phosphopeptides in this mixture dominate the MS spectrum (Fig. 3a) so that even the most abundant phosphopeptide, p3, is severely suppressed and hardly observable. After enrichment, 28 multiply charged MS peaks corresponding to 18 phosphorylated peptides were identified (Fig. 3b). Note all of the phosphopetides and phosphorylation sites identified from the peptide mixture digested from pure  $\alpha$ -casein, including those of very low abundance, were recovered from this highly complex peptide mixture, underlining the high specificity of this enrichment. The sequences of all the identified phosphorylated peptides in Fig. 2, 3, and S3 are summarized in Table S4. Overall, we have identified 18 unique phosphorylation sites (out of a total of 21 potential phosphorylation sites) for  $\alpha$ -case in (s1 and s2 variants)<sup>12</sup> from a single enrichment using mesoporous ZrO<sub>2</sub>. Such highly effective and specific enrichment of phosphopeptides out of the peptide mixtures with mesoporous ZrO<sub>2</sub>, which could almost be considered as "purification", allows a robust analysis of the phosphopeptides.

In conclusion, we have demonstrated the first use of mesoprous  $ZrO_2$  nanomaterials for simple and highly effective enrichment of phosphopeptides. These materials enrich phosphopeptides with high specificity which allows a more comprehensive and efficient phosphoproteomic analysis. Proper engineering of the mesoporous materials in terms of chemical composition, porosity, surface area, and pore structures and further optimization of the enrichment procedures will enhance their performance even further. These results open up the exploitation of mesoporous metal oxide nanomaterials for their practical applications in MS-based phosphoproteomic study of complex biological samples, which are curently in progess.

#### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

#### Acknowledgments

This work is supported by US National Institutes of Health (NIH) CA126701 and UW-Madison IEDR and Draper TIF grants.

Chem Commun (Camb). Author manuscript; available in PMC 2010 November 21.

#### Notes and references

- (a) Hunter T. Cell 2000;100:113–127. [PubMed: 10647936] (b) Pawson T, Nash P. Science 2003;300:445–452. [PubMed: 12702867] (c) Jumaa H, Hendricks RW, Reth MB. Annu. Rev. Immunol 2005;23:415–445. [PubMed: 15771577]
- 2. (a) McLafferty FW, Fridriksson EK, Horn DM, Lewis MA, Zubarev RA. Science 1999;284:1289–1290. [PubMed: 10383309] (b) McLachlin DT, Chait BT. Curr. Opin. Chem. Biol 2001;5:591–602. [PubMed: 11578935] (c) Huang PH, White FM. Mol. Cell 2008;31:777–781. [PubMed: 18922462] (d) Carr SA, Huddleston MJ, Annan RS. Anal. Biochem 1996;239:180–192. [PubMed: 8811904]
- (a) Mann M, Ong SE, Gronborg M, Steen H, Jensen ON, Pandey A. Trends Biotechnol 2002;20:261–268. [PubMed: 12007495] (b) Steen H, Jebanathirajah JA, Rush J, Morrice N, Kirschner MW. Mol. Cell. Proteomics 2006;5:172–181. [PubMed: 16204703]
- 4. (a) Bodenmiller B, Mueller LN, Mueller M, Domon B, Aebersold R. Nat. Methods 2007;4:231–237.
  [PubMed: 17293869] (b) Oda Y, Nagasu T, Chait BT. Nat. Biotechnol 2001;19:379–382. [PubMed: 11283599] (c) Tao WA, Wollscheid B, O'Brien R, Eng JK, Li XJ, Bodenmiller B, Watts JD, Hood L, Aebersold R. Nat. Methods 2005;2:591–598. [PubMed: 16094384]
- (a) Porath J, Carlsson J, Olsson I, Belfrage G. Nature 1975;258:598–599. [PubMed: 1678] (b) Posewitz MC, Tempst P. Anal. Chem 1999;71:2883–2892. [PubMed: 10424175] (c) Zhang X, Ye JY, Jensen ON, Roepstorff P. Mol. Cell. Proteomics 2007;6:2032–2042. [PubMed: 17675664] (d) Ficarro SB, McCleland ML, Stukenberg PT, Burke DJ, Ross MM, Shabanowitz J, Hunt DF, White FM. Nat. Biotechnol 2002;20:301–305. [PubMed: 11875433] (e) Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Proc. Natl. Acad. Sci. U.S.A 2007;104:5860–5865. [PubMed: 17389395]
- 6. (a) Pinkse MWH, Uitto PM, Hilhorst MJ, Ooms B, Heck AJR. Anal. Chem 2004;76:3935–3943. [PubMed: 15253627] (b) Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, Jorgensen TJD. Mol. Cell. Proteomics 2005;4:873–886. [PubMed: 15858219] (c) Kweon HK, Hakansson K. Anal. Chem 2006;78:1743–1749. [PubMed: 16536406] (d) Han L, Shan Z, Chen DH, Yu XJ, Yang PY, Tu B, Zhao DY. J. Colloid. Interface Sci 2008;318:315–321. [PubMed: 18001758] (e) Ficarro SB, Parikh JR, Blank NC, Marto JA. Anal. Chem 2008;80:4606–4613. [PubMed: 18491922]
- 7. (a) Chen CT, Chen YC. Anal. Chem 2005;77:5912–5919. [PubMed: 16159121] (b) Zhou HJ, Tian RJ, Reth MB, Xu SY, Feng S, Pan CS, Jiang XG, Li X, Zou HF. Electrophoresis 2007;28:2201–2215. [PubMed: 17539039]
- (a) Yang PD, Zhao DY, Margolese DI, Chmelka BF, Stucky GD. Nature 1998;396:152–155. (b) Yang PD, Zhao DY, Margolese DI, Chmelka BF, Stucky GD. Chem. Mater 1999;11:2813–2826. (c) Brinker CJ, Lu YF, Sellinger A, Fan HY. Advanced Materials 1999;11:579–585. (d) Lu YF, Ganguli R, Drewien CA, Anderson MT, Brinker CJ, Gong WL, Guo YX, Soyez H, Dunn B, Huang MH, Zink JI. Nature 1997;389:364–368. (e) Fan J, Boettcher SW, Stucky GD. Chem. Mater 2006;18:6391–6396. (f) Tian B, Yang H, Liu X, Xie S, Yu C, Fan J, Tu B. D. Zhao Chem. Comm 2002;17:1824–1825.
- 9. (a) Zhou H, Xu S, Ye M, Feng S, Pan C, Jiang X, Li X, Han G, Fu Y, Zou H. J. Proteome Res 2006;5:2431–2437. [PubMed: 16944956] (b) Hu L, Zhou H, Li Y, Sun S, Guo L, Ye M, Tian X, Gu J, Yang S, Zou H. Anal. Chem 2009;81:94–104. [PubMed: 19117447]
- (a) Nawrocki J, Rigney J, McCormick A, Carr PW. J. Chromatogr. A 1993;657:229–282. [PubMed: 8130879] (b) Rai D, Xia YX, Hess NJ, Strachan DM, McGrail BP. J. Solution Chem 2001;30:949–967.
- (a) Zubarev RA, Kelleher NL, McLafferty FW. J. Am. Chem. Soc 1998;120:3265–3266. (b) Ge Y, Lawhorn BG, ElNaggar M, Strauss E, Park JH, Begley TP, McLafferty FW. J. Am.Chem. Soc 2002;124:672–678. [PubMed: 11804498] (c) Shi SDH, Hemling ME, Carr SA, Horn DM, Lindh I, McLafferty FW. Anal. Chem 2001;73:19–22. [PubMed: 11195502] (d) Breuker K, McLafferty FW. Angew. Chem. Int. Ed 2003;42:4900–4904.
- 12. http://www.expasy.ch/sprot/

Nelson et al.





TEM micrograph for mesoporous  $ZrO_2$  (a) with its corresponding SAXS pattern (b) and nitrogen adsorption-desorption isotherms (c).

Nelson et al.



Negative ion mode ESI/FTMS spectra of peptide mixtures digested from  $\alpha$ -casein with trypsin acquired after enrichment with (a) a leading commercial IMAC-based product, (b) a leading commercial product of ZrO<sub>2</sub> packed tip, and (c) the mesoporous ZrO<sub>2</sub> nanomaterials. Phosphopeptides are labeled with numbers that are shown in Table S4.

Nelson et al.



#### Fig. 3.

Negative ion mode ESI/FTMS spectra of peptide mixtures digested with trypsin acquired before enrichment (a), and after enrichment with mesoporous  $ZrO_2$  (b). Circle, double circle, triangle, square, and star indicate singly, doubly, triply, quadruply, and quintuply phosphorylated peptides, respectively. Phosphopeptides are labeled with numbers that are identified and shown in Table S4. Insets are expanded MS spectra at m/z 962.

Nelson et al.



Scheme 1.

Flow diagram of phosphopeptide enrichment procedure.

Chem Commun (Camb). Author manuscript; available in PMC 2010 November 21.